Betta Pharmaceuticals announced that three of its products have been included in the National Essential Medicines List, 2026 edition. Among them, bevacizumab is a new addition, while icotinib and trastuzumab remain on the list. This inclusion reflects strong clinical recognition of the products' efficacy. Essential Medicines List products, supported by policies such as tiered diagnosis and treatment and medical consortium development, can achieve full coverage across medical institutions at all levels, further penetrate primary care, and significantly improve drug accessibility. This has a positive impact on boosting product sales. In the first quarter of 2026, Betta Pharmaceuticals achieved revenue of 1.04 billion yuan and net profit attributable to the parent company of 236 million yuan.
Betta Pharmaceuticals Co LtdBevacizumab newly added to National Essential Medicines List, boosting product sales through expanded coverage and accessibility.